Chan YH, Wu LS, See LC, et al. - Utilizing data from the Taiwan National Health Insurance Research Database, researchers conducted a nationwide retrospective cohort study to test the safety and efficacy of direct oral anticoagulants (DOACs) in non-valvular atrial fibrillation (NVAF) Asian patients with concomitant hyperthyroidism. From June 1, 2012, to December 31, 2017, a total of 3,213 and 1,181 NVAF patients with hyperthyroidism taking DOACs and warfarin, respectively, were enrolled. In addition, 53,591 and 16,564 NVAF patients without hyperthyroidism taking DOACs and warfarin, respectively, were recruited. Findings suggested that DOACs can be an effective and safer alternative to warfarin among NVAF Asian patients with concomitant hyperthyroidism. For such patients, thromboprophylaxis with DOACs may be considered, and validation of this finding is important in further prospective study.